BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Stemline Therapeutics, Inc. (“Stemline” or the “Company”) (NASDAQ: STML) investors concerning the Company and its officers’ possible violations of federal securities laws.
Stemline is a clinical stage biopharmaceutical company that focuses on the discovery, acquisition, development and commercialization of proprietary oncology therapeutics in the United States.
On or around January 19, 2017 Stemline announced a proposed secondary offering of 4.5 million shares at $10 per share. Then on February 2, 2017, Bloomberg announced a patient death in a clinical trial for Stemline’s cancer drug SL-401. The third death attributed in part to SL-401.
On this news, the Company's stock fell $4.15 per share, or 42%, to close on February 2, 2017 at $5.60 a share.
If you purchased Stemline securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.